Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 16/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3601102 | 1.00 | NPC1 (1.00) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| Bromide SCHEMBL3595600 | 1.00 | NPC1 (1.00) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL4890046 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3603641 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3592351 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3606677 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3600997 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| SCHEMBL3598215 | 0.98 | NPC1 (0.96) | NPC1POLBRAB9ASMN1; SMN2BCHE | |
| Bromide SCHEMBL635435 | 0.92 | SMN1; SMN2 (0.85) | NPC1POLBRAB9ASMN1; SMN2ACHE | |
| Bromide SCHEMBL4079693 | 0.92 | SMN1; SMN2 (0.85) | NPC1POLBRAB9ASMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287490-A1 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-20050261334-A1 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261334-A1 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies | SLC18A3, SLC18A2, CHRNB2 | ACHE 43/4885NPC1 440/4885POLB 1522/4885 |
| US-20080287490-A1 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies | SLC18A3, SLC18A2, CHRNB2 | ACHE 43/4885NPC1 440/4885POLB 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.